Journal
JOURNAL OF VIROLOGY
Volume 84, Issue 2, Pages 1005-1013Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.01809-09
Keywords
-
Categories
Funding
- Swiss National Science Foundation [3100A0-112678]
- Ministero del Lavoro, della Salute e delle Politiche Sociali, Ricerca Finalizzata [89301]
- Fondazione CARIPLO [93005]
- Swiss Vaccine Research Institute
- Helmut Horten Foundation
Ask authors/readers for more resources
Human cytomegalovirus (HCMV) is a widely circulating pathogen that causes severe disease in immuno-compromised patients and infected fetuses. By immortalizing memory B cells from HCMV-immune donors, we isolated a panel of human monoclonal antibodies that neutralized at extremely low concentrations (90% inhibitory concentration [IC(90)] values ranging from 5 to 200 pM) HCMV infection of endothelial, epithelial, and myeloid cells. With the single exception of an antibody that bound to a conserved epitope in the UL128 gene product, all other antibodies bound to conformational epitopes that required expression of two or more proteins of the gH/gL/UL128-131A complex. Antibodies against gB, gH, or gM/gN were also isolated and, albeit less potent, were able to neutralize infection of both endothelial-epithelial cells and fibroblasts. This study describes unusually potent neutralizing antibodies against HCMV that might be used for passive immunotherapy and identifies, through the use of such antibodies, novel antigenic targets in HCMV for the design of immunogens capable of eliciting previously unknown neutralizing antibody responses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available